EGFR and non-small cell lung carcinoma: If future investigations elucidate the mechanisms of toxicity and clinical situations in which toxicity develops, it might be possible to provide better treatment options and clinical benefits to patients with EGFR-mutated NSCLC and high PD-L1 expression.